Michael Kahn
Concepts (444)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta Catenin | 17 | 2024 | 252 | 4.200 |
Why?
| | Wnt Signaling Pathway | 13 | 2024 | 210 | 2.530 |
Why?
| | Electronic Health Records | 22 | 2024 | 1169 | 2.400 |
Why?
| | Data Accuracy | 8 | 2026 | 65 | 1.740 |
Why?
| | CREB-Binding Protein | 5 | 2019 | 34 | 1.720 |
Why?
| | Medical Informatics | 6 | 2017 | 97 | 1.600 |
Why?
| | Neoplastic Stem Cells | 8 | 2021 | 412 | 1.470 |
Why?
| | Biomedical Research | 10 | 2026 | 709 | 1.430 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2024 | 127 | 1.370 |
Why?
| | Medical Record Linkage | 9 | 2024 | 68 | 1.330 |
Why?
| | Pediatrics | 6 | 2019 | 1112 | 1.200 |
Why?
| | p300-CBP Transcription Factors | 3 | 2018 | 26 | 1.180 |
Why?
| | Catenins | 2 | 2018 | 6 | 1.070 |
Why?
| | Crowding | 3 | 2011 | 37 | 1.020 |
Why?
| | Health Services Research | 3 | 2019 | 394 | 0.900 |
Why?
| | Pyrimidinones | 7 | 2018 | 126 | 0.840 |
Why?
| | Computer Communication Networks | 2 | 2014 | 32 | 0.840 |
Why?
| | Comparative Effectiveness Research | 5 | 2017 | 169 | 0.820 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 8 | 2018 | 279 | 0.800 |
Why?
| | Quality of Health Care | 4 | 2013 | 688 | 0.740 |
Why?
| | Imatinib Mesylate | 2 | 2024 | 77 | 0.740 |
Why?
| | Rare Diseases | 1 | 2023 | 113 | 0.730 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.730 |
Why?
| | Cloud Computing | 1 | 2022 | 6 | 0.730 |
Why?
| | E1A-Associated p300 Protein | 2 | 2019 | 13 | 0.700 |
Why?
| | Glioma | 2 | 2024 | 425 | 0.670 |
Why?
| | Patient-Centered Care | 3 | 2014 | 540 | 0.640 |
Why?
| | Information Storage and Retrieval | 5 | 2020 | 121 | 0.620 |
Why?
| | Clinical Trials as Topic | 5 | 2017 | 1050 | 0.600 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 336 | 0.590 |
Why?
| | Machine Learning | 2 | 2023 | 585 | 0.540 |
Why?
| | Genomic Instability | 1 | 2018 | 66 | 0.530 |
Why?
| | Urology | 1 | 2018 | 64 | 0.520 |
Why?
| | gamma Catenin | 1 | 2017 | 13 | 0.520 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2017 | 18 | 0.520 |
Why?
| | Child Health | 1 | 2019 | 157 | 0.510 |
Why?
| | Humans | 85 | 2026 | 144261 | 0.500 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 145 | 0.490 |
Why?
| | Models, Statistical | 3 | 2026 | 677 | 0.470 |
Why?
| | Hematopoiesis | 1 | 2017 | 194 | 0.470 |
Why?
| | Medical Records Systems, Computerized | 4 | 2012 | 95 | 0.470 |
Why?
| | Radiation Injuries | 1 | 2017 | 151 | 0.460 |
Why?
| | Data Mining | 2 | 2017 | 117 | 0.460 |
Why?
| | Databases, Factual | 6 | 2019 | 1484 | 0.450 |
Why?
| | Child Welfare | 2 | 2014 | 231 | 0.440 |
Why?
| | Cell Line, Tumor | 12 | 2024 | 3539 | 0.420 |
Why?
| | Evolution, Molecular | 1 | 2018 | 513 | 0.420 |
Why?
| | Forms and Records Control | 1 | 2013 | 20 | 0.410 |
Why?
| | Community Networks | 1 | 2014 | 57 | 0.400 |
Why?
| | Terminology as Topic | 2 | 2014 | 255 | 0.400 |
Why?
| | Quality Indicators, Health Care | 3 | 2013 | 335 | 0.380 |
Why?
| | Quality Improvement | 1 | 2021 | 1285 | 0.370 |
Why?
| | Population Surveillance | 3 | 2020 | 483 | 0.360 |
Why?
| | Nursing Assessment | 1 | 2011 | 56 | 0.330 |
Why?
| | Analgesia | 1 | 2011 | 105 | 0.330 |
Why?
| | Embryonic Stem Cells | 1 | 2011 | 130 | 0.330 |
Why?
| | Antineoplastic Agents | 4 | 2021 | 2192 | 0.330 |
Why?
| | Wearable Electronic Devices | 2 | 2021 | 63 | 0.320 |
Why?
| | Cell Differentiation | 4 | 2024 | 2048 | 0.320 |
Why?
| | MicroRNAs | 4 | 2021 | 700 | 0.320 |
Why?
| | Mice | 16 | 2024 | 18329 | 0.310 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2010 | 81 | 0.300 |
Why?
| | Information Dissemination | 3 | 2019 | 220 | 0.300 |
Why?
| | Pain | 2 | 2011 | 777 | 0.300 |
Why?
| | Child | 17 | 2020 | 22537 | 0.300 |
Why?
| | Animals | 21 | 2024 | 38030 | 0.290 |
Why?
| | Emergency Service, Hospital | 2 | 2011 | 2301 | 0.290 |
Why?
| | Luciferases | 2 | 2019 | 152 | 0.280 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 265 | 0.270 |
Why?
| | United States | 18 | 2022 | 15876 | 0.270 |
Why?
| | Mass Screening | 2 | 2020 | 1332 | 0.270 |
Why?
| | Accidental Falls | 1 | 2011 | 222 | 0.270 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 913 | 0.260 |
Why?
| | Algorithms | 5 | 2024 | 1834 | 0.260 |
Why?
| | Organizational Policy | 1 | 2007 | 74 | 0.250 |
Why?
| | Pregnenes | 1 | 2006 | 1 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2020 | 2516 | 0.240 |
Why?
| | Fluorine | 1 | 2006 | 17 | 0.240 |
Why?
| | Patient Access to Records | 1 | 2026 | 20 | 0.240 |
Why?
| | Pain Management | 2 | 2025 | 405 | 0.240 |
Why?
| | Health Records, Personal | 1 | 2026 | 26 | 0.240 |
Why?
| | Pain Clinics | 1 | 2025 | 3 | 0.230 |
Why?
| | Cell Proliferation | 6 | 2023 | 2494 | 0.230 |
Why?
| | Wnt Proteins | 4 | 2016 | 133 | 0.230 |
Why?
| | Transitional Care | 1 | 2025 | 46 | 0.220 |
Why?
| | Receptors, Glucocorticoid | 1 | 2006 | 138 | 0.220 |
Why?
| | Emergency Medical Services | 1 | 2011 | 696 | 0.210 |
Why?
| | Patient Care Team | 2 | 2025 | 686 | 0.210 |
Why?
| | Biological Science Disciplines | 1 | 2024 | 16 | 0.210 |
Why?
| | Knowledge Bases | 1 | 2024 | 28 | 0.210 |
Why?
| | Data Interpretation, Statistical | 1 | 2026 | 371 | 0.210 |
Why?
| | Neoplasms | 2 | 2017 | 2870 | 0.210 |
Why?
| | Adolescent | 16 | 2022 | 22281 | 0.200 |
Why?
| | Pattern Recognition, Automated | 1 | 2024 | 74 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2020 | 3842 | 0.200 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 53 | 0.200 |
Why?
| | Child, Preschool | 9 | 2020 | 11774 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2025 | 1131 | 0.200 |
Why?
| | Time Factors | 5 | 2025 | 7155 | 0.190 |
Why?
| | Cell Line | 6 | 2019 | 2879 | 0.190 |
Why?
| | Phenotype | 3 | 2023 | 3157 | 0.190 |
Why?
| | Adrenal Cortex Hormones | 1 | 2006 | 478 | 0.190 |
Why?
| | Cell Movement | 5 | 2023 | 965 | 0.190 |
Why?
| | Asthma | 3 | 2011 | 1767 | 0.190 |
Why?
| | Data Collection | 3 | 2014 | 633 | 0.190 |
Why?
| | Androgens | 1 | 2024 | 186 | 0.180 |
Why?
| | Chronic Disease | 2 | 2019 | 1812 | 0.180 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 732 | 0.180 |
Why?
| | Mouth Neoplasms | 1 | 2023 | 90 | 0.180 |
Why?
| | Pyrazoles | 1 | 2006 | 509 | 0.180 |
Why?
| | Precision Medicine | 2 | 2024 | 456 | 0.180 |
Why?
| | Pyridines | 1 | 2006 | 605 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 163 | 0.170 |
Why?
| | Infant | 7 | 2020 | 10022 | 0.170 |
Why?
| | Life Cycle Stages | 1 | 2021 | 37 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 293 | 0.170 |
Why?
| | Hyaluronan Receptors | 2 | 2018 | 102 | 0.170 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 621 | 0.160 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 1 | 2020 | 8 | 0.160 |
Why?
| | Recurrence | 1 | 2024 | 1134 | 0.160 |
Why?
| | Education, Distance | 1 | 2021 | 61 | 0.160 |
Why?
| | Tumor Stem Cell Assay | 2 | 2018 | 34 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 370 | 0.160 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 431 | 0.160 |
Why?
| | Internet | 2 | 2017 | 698 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 881 | 0.150 |
Why?
| | Colorado | 8 | 2024 | 4562 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2022 | 247 | 0.150 |
Why?
| | India | 4 | 2020 | 218 | 0.150 |
Why?
| | Chromatin | 1 | 2024 | 561 | 0.150 |
Why?
| | Information Services | 1 | 2019 | 45 | 0.150 |
Why?
| | Information Management | 2 | 2012 | 16 | 0.150 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 46 | 0.150 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 592 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 652 | 0.150 |
Why?
| | Young Adult | 8 | 2020 | 13990 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 265 | 0.140 |
Why?
| | Penicillin Resistance | 1 | 1998 | 8 | 0.140 |
Why?
| | Cell Cycle Proteins | 1 | 2023 | 628 | 0.140 |
Why?
| | 3T3 Cells | 1 | 2019 | 156 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 225 | 0.140 |
Why?
| | Acute Disease | 2 | 2011 | 1028 | 0.140 |
Why?
| | Male | 18 | 2025 | 72035 | 0.140 |
Why?
| | Female | 20 | 2025 | 77976 | 0.140 |
Why?
| | Metabolic Syndrome | 1 | 2022 | 352 | 0.140 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 576 | 0.140 |
Why?
| | Toxicity Tests | 1 | 2018 | 38 | 0.130 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3403 | 0.130 |
Why?
| | Multimedia | 1 | 2017 | 13 | 0.130 |
Why?
| | Adult | 12 | 2025 | 40262 | 0.130 |
Why?
| | Cisplatin | 2 | 2021 | 334 | 0.130 |
Why?
| | Colorectal Neoplasms | 2 | 2020 | 844 | 0.130 |
Why?
| | Pneumococcal Infections | 1 | 1998 | 103 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 623 | 0.130 |
Why?
| | Research Design | 4 | 2021 | 1129 | 0.130 |
Why?
| | Liver Neoplasms | 2 | 2022 | 780 | 0.130 |
Why?
| | Datasets as Topic | 1 | 2017 | 122 | 0.130 |
Why?
| | Infant, Newborn | 5 | 2020 | 6424 | 0.130 |
Why?
| | Signal Transduction | 5 | 2015 | 5221 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1137 | 0.130 |
Why?
| | Computer-Assisted Instruction | 1 | 2017 | 71 | 0.130 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 209 | 0.130 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 132 | 0.130 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2017 | 139 | 0.120 |
Why?
| | Pain Measurement | 2 | 2025 | 552 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2015 | 219 | 0.120 |
Why?
| | Fractures, Bone | 2 | 2011 | 414 | 0.120 |
Why?
| | Hospitals, University | 2 | 2011 | 176 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 928 | 0.120 |
Why?
| | Vocabulary, Controlled | 2 | 2014 | 47 | 0.120 |
Why?
| | Cross Infection | 1 | 1998 | 262 | 0.120 |
Why?
| | Adult Stem Cells | 1 | 2016 | 39 | 0.120 |
Why?
| | Logistic Models | 2 | 2011 | 2104 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2011 | 5813 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 862 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2023 | 1455 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 337 | 0.110 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 72 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 586 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 442 | 0.110 |
Why?
| | Antigens, CD | 1 | 2018 | 555 | 0.110 |
Why?
| | Protein Kinase C | 1 | 2016 | 252 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2015 | 92 | 0.110 |
Why?
| | Program Development | 2 | 2019 | 369 | 0.100 |
Why?
| | Hydronephrosis | 1 | 2014 | 35 | 0.100 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 78 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 555 | 0.100 |
Why?
| | Database Management Systems | 2 | 2012 | 50 | 0.100 |
Why?
| | Organizational Innovation | 1 | 2014 | 120 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2015 | 197 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 420 | 0.100 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 192 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.100 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1313 | 0.100 |
Why?
| | Odds Ratio | 2 | 2011 | 1072 | 0.100 |
Why?
| | Interinstitutional Relations | 1 | 2013 | 53 | 0.100 |
Why?
| | Patient Identification Systems | 1 | 2013 | 16 | 0.100 |
Why?
| | Models, Theoretical | 2 | 2017 | 582 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 257 | 0.100 |
Why?
| | Patient Handoff | 1 | 2013 | 42 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2018 | 4146 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 557 | 0.090 |
Why?
| | Postoperative Period | 1 | 2013 | 353 | 0.090 |
Why?
| | Ethics Committees, Research | 1 | 2012 | 41 | 0.090 |
Why?
| | TCF Transcription Factors | 1 | 2011 | 19 | 0.090 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2011 | 45 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2182 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 402 | 0.090 |
Why?
| | Risk Assessment | 2 | 2011 | 3637 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2022 | 17009 | 0.090 |
Why?
| | Documentation | 1 | 2013 | 197 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1092 | 0.090 |
Why?
| | Operating Rooms | 1 | 2013 | 146 | 0.090 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2011 | 47 | 0.090 |
Why?
| | Narcotics | 1 | 2011 | 55 | 0.080 |
Why?
| | Bed Occupancy | 1 | 2011 | 16 | 0.080 |
Why?
| | Research | 1 | 2014 | 428 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2011 | 333 | 0.080 |
Why?
| | Registries | 4 | 2020 | 2382 | 0.080 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2011 | 148 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 177 | 0.080 |
Why?
| | Protein Binding | 1 | 2017 | 2270 | 0.080 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 8 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1057 | 0.080 |
Why?
| | Structure-Activity Relationship | 2 | 2014 | 567 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2314 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 376 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2012 | 284 | 0.080 |
Why?
| | Child, Hospitalized | 1 | 2010 | 54 | 0.080 |
Why?
| | Analgesics | 1 | 2011 | 228 | 0.070 |
Why?
| | Injury Severity Score | 1 | 2011 | 600 | 0.070 |
Why?
| | Ambulatory Care | 1 | 2014 | 597 | 0.070 |
Why?
| | Intubation, Intratracheal | 1 | 2012 | 320 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2012 | 462 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 842 | 0.070 |
Why?
| | Patient Safety | 1 | 2013 | 347 | 0.070 |
Why?
| | Clinical Competence | 1 | 2017 | 1241 | 0.070 |
Why?
| | Anti-Asthmatic Agents | 1 | 2011 | 251 | 0.070 |
Why?
| | Needs Assessment | 1 | 2011 | 401 | 0.070 |
Why?
| | RNA, Small Interfering | 3 | 2018 | 634 | 0.070 |
Why?
| | Estrogens | 1 | 2011 | 380 | 0.070 |
Why?
| | Workflow | 1 | 2010 | 184 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 536 | 0.070 |
Why?
| | Overweight | 1 | 2013 | 606 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 680 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1867 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2012 | 395 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2603 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1533 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2013 | 916 | 0.060 |
Why?
| | Inpatients | 1 | 2011 | 542 | 0.060 |
Why?
| | Stereoisomerism | 1 | 2006 | 104 | 0.060 |
Why?
| | Microwaves | 1 | 2006 | 31 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 627 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2013 | 624 | 0.060 |
Why?
| | Mutation | 3 | 2022 | 4085 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1318 | 0.060 |
Why?
| | Confidentiality | 1 | 2026 | 79 | 0.060 |
Why?
| | Ontario | 1 | 2025 | 96 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1125 | 0.060 |
Why?
| | Ambulatory Care Information Systems | 1 | 2005 | 5 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1495 | 0.050 |
Why?
| | Indiana | 1 | 2024 | 37 | 0.050 |
Why?
| | Molecular Structure | 1 | 2006 | 498 | 0.050 |
Why?
| | Aqueous Humor | 2 | 1983 | 38 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 323 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 729 | 0.050 |
Why?
| | Patient Readmission | 1 | 2010 | 756 | 0.050 |
Why?
| | Hepatocyte Growth Factor | 1 | 2024 | 33 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2018 | 744 | 0.050 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2023 | 9 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2024 | 121 | 0.050 |
Why?
| | Ribosomal Proteins | 1 | 2024 | 91 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1739 | 0.050 |
Why?
| | Mice, Nude | 2 | 2015 | 682 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 91 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2010 | 725 | 0.050 |
Why?
| | Hospitals, General | 1 | 2022 | 25 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 101 | 0.050 |
Why?
| | Trabecular Meshwork | 1 | 1983 | 80 | 0.050 |
Why?
| | Receptors, Androgen | 1 | 2024 | 153 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1627 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2815 | 0.050 |
Why?
| | Health Insurance Portability and Accountability Act | 1 | 2022 | 13 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 2193 | 0.050 |
Why?
| | Bronchial Diseases | 1 | 2002 | 38 | 0.040 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2002 | 51 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2006 | 533 | 0.040 |
Why?
| | Middle Aged | 5 | 2025 | 35762 | 0.040 |
Why?
| | Glutathione | 1 | 1983 | 375 | 0.040 |
Why?
| | Immune Evasion | 1 | 2022 | 64 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2010 | 1091 | 0.040 |
Why?
| | Hepatitis B | 1 | 2022 | 66 | 0.040 |
Why?
| | Fitness Trackers | 1 | 2021 | 16 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1983 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 128 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2002 | 97 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 547 | 0.040 |
Why?
| | Collagen | 1 | 2023 | 455 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2016 | 1255 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 25 | 0.040 |
Why?
| | Piperidines | 1 | 2002 | 217 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2002 | 282 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2020 | 157 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 152 | 0.040 |
Why?
| | Prospective Studies | 3 | 2020 | 7970 | 0.040 |
Why?
| | Receptors, Antigen | 1 | 2019 | 14 | 0.040 |
Why?
| | Probability | 1 | 2020 | 308 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 919 | 0.040 |
Why?
| | Demography | 1 | 2020 | 284 | 0.040 |
Why?
| | Bias | 1 | 2020 | 201 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2447 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1487 | 0.040 |
Why?
| | Missouri | 1 | 1998 | 66 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5935 | 0.030 |
Why?
| | Genomics | 1 | 2024 | 833 | 0.030 |
Why?
| | Consumer Product Safety | 1 | 2018 | 32 | 0.030 |
Why?
| | Computer Systems | 1 | 2018 | 56 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6021 | 0.030 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2017 | 44 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 850 | 0.030 |
Why?
| | Artificial Intelligence | 1 | 2002 | 365 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 382 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4278 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2014 | 1253 | 0.030 |
Why?
| | North America | 1 | 2017 | 310 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2016 | 3119 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 1998 | 174 | 0.030 |
Why?
| | Aquaporin 5 | 1 | 2016 | 3 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2019 | 674 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2016 | 24 | 0.030 |
Why?
| | Gastrostomy | 1 | 2017 | 130 | 0.030 |
Why?
| | Tracheostomy | 1 | 2017 | 142 | 0.030 |
Why?
| | Electric Impedance | 1 | 2016 | 111 | 0.030 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2015 | 20 | 0.030 |
Why?
| | Students | 1 | 2021 | 661 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2017 | 222 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 668 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1172 | 0.030 |
Why?
| | Alveolar Epithelial Cells | 1 | 2016 | 120 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2111 | 0.030 |
Why?
| | Ubiquitination | 1 | 2015 | 118 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2015 | 193 | 0.030 |
Why?
| | Health Planning Guidelines | 1 | 2014 | 24 | 0.030 |
Why?
| | SOXB1 Transcription Factors | 1 | 2015 | 67 | 0.030 |
Why?
| | Drug Synergism | 1 | 2015 | 357 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 91 | 0.030 |
Why?
| | Calibration | 1 | 2014 | 151 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 176 | 0.030 |
Why?
| | Drug Design | 1 | 2015 | 173 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 102 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 321 | 0.030 |
Why?
| | Semantics | 1 | 2014 | 100 | 0.030 |
Why?
| | Albumins | 1 | 2014 | 118 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2014 | 117 | 0.030 |
Why?
| | Podocytes | 1 | 2014 | 80 | 0.020 |
Why?
| | ras Proteins | 1 | 2014 | 150 | 0.020 |
Why?
| | Pandemics | 1 | 2022 | 1682 | 0.020 |
Why?
| | Carcinoma | 1 | 2015 | 227 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 476 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2870 | 0.020 |
Why?
| | Names | 1 | 2013 | 15 | 0.020 |
Why?
| | Drug Discovery | 1 | 2014 | 154 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 477 | 0.020 |
Why?
| | Systems Integration | 1 | 2013 | 36 | 0.020 |
Why?
| | Computer Simulation | 1 | 2017 | 1025 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 321 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 163 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2014 | 5389 | 0.020 |
Why?
| | Airway Extubation | 1 | 2013 | 60 | 0.020 |
Why?
| | Research Personnel | 1 | 2014 | 183 | 0.020 |
Why?
| | Aged | 2 | 2025 | 25850 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 505 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 673 | 0.020 |
Why?
| | Snail Family Transcription Factors | 1 | 2011 | 18 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2012 | 43 | 0.020 |
Why?
| | Medical Errors | 1 | 2013 | 118 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1732 | 0.020 |
Why?
| | Gene Targeting | 1 | 2011 | 82 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2014 | 724 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1327 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2011 | 139 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2829 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1982 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2011 | 149 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3166 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 545 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2926 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1087 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 528 | 0.020 |
Why?
| | Actins | 1 | 2012 | 422 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2011 | 610 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1182 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 688 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2011 | 479 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1264 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2013 | 707 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2011 | 437 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5592 | 0.020 |
Why?
| | Internship and Residency | 1 | 2017 | 1255 | 0.020 |
Why?
| | Kidney | 1 | 2014 | 1495 | 0.020 |
Why?
| | Information Centers | 1 | 2005 | 2 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1559 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1953 | 0.010 |
Why?
| | Hospitals | 1 | 2010 | 727 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 71 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2020 | 11643 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1782 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2420 | 0.010 |
Why?
| | Diamide | 1 | 1983 | 4 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1347 | 0.010 |
Why?
| | Iodoacetates | 1 | 1983 | 3 | 0.010 |
Why?
| | Iodoacetamide | 1 | 1983 | 5 | 0.010 |
Why?
| | Ethylmaleimide | 1 | 1983 | 18 | 0.010 |
Why?
| | Carmustine | 1 | 1983 | 52 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4556 | 0.010 |
Why?
| | Sulfhydryl Reagents | 1 | 1983 | 12 | 0.010 |
Why?
| | Anterior Chamber | 1 | 1983 | 27 | 0.010 |
Why?
| | Free Radicals | 1 | 1983 | 110 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4254 | 0.010 |
Why?
| | Rabbits | 1 | 1983 | 648 | 0.010 |
Why?
| | Tryptases | 1 | 2002 | 13 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 40 | 0.010 |
Why?
| | Pulmonary Eosinophilia | 1 | 2002 | 26 | 0.010 |
Why?
| | Lens, Crystalline | 1 | 1983 | 136 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 1983 | 336 | 0.010 |
Why?
| | Time | 1 | 2002 | 86 | 0.010 |
Why?
| | Pulmonary Edema | 1 | 2002 | 106 | 0.010 |
Why?
| | Ovalbumin | 1 | 2002 | 190 | 0.010 |
Why?
| | Bronchial Hyperreactivity | 1 | 2002 | 96 | 0.010 |
Why?
| | Mucus | 1 | 2002 | 73 | 0.010 |
Why?
| | Cattle | 1 | 1983 | 999 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1983 | 1084 | 0.010 |
Why?
| | Amino Acids | 1 | 1983 | 521 | 0.010 |
Why?
| | Eosinophils | 1 | 2002 | 316 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 636 | 0.010 |
Why?
| | Glucose | 1 | 1983 | 1046 | 0.010 |
Why?
| | Risk Factors | 1 | 2012 | 10699 | 0.010 |
Why?
| | Decision Support Techniques | 1 | 2002 | 454 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1618 | 0.010 |
Why?
| | Cytokines | 1 | 2002 | 2061 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2877 | 0.000 |
Why?
| | Lung | 1 | 2002 | 4108 | 0.000 |
Why?
|
|
Kahn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|